Medacta Calls 2026 AGM With Dividend and Board Re-Elections on Agenda

An update from Medacta Group SA ( (CH:MOVE) ) is now available.

Medacta Group SA has issued the invitation to its 2026 Annual General Meeting, scheduled for 5 May 2026 at its premises in Rancate, Switzerland, where shareholders may attend in person or vote via independent or third-party proxies. The Board will ask investors to approve a CHF 21.9 million dividend, equivalent to CHF 1.10 per share, and to re-elect Chairman Dr. Alberto Siccardi, the current board, the Remuneration Committee, the Independent Proxy Holder, the auditors, and the proposed compensation caps for directors and executive management.

The proposed dividend underscores Medacta’s willingness to return capital to shareholders while maintaining continuity in its governance structure. By seeking broad re-elections and confirming oversight roles, the company signals strategic stability, which may reassure investors and stakeholders as it pursues growth in the competitive global medtech sector.

The most recent analyst rating on (CH:MOVE) stock is a Buy with a CHF185.00 price target. To see the full list of analyst forecasts on Medacta Group SA stock, see the CH:MOVE Stock Forecast page.

More about Medacta Group SA

Medacta Group SA is a Swiss medical technology company specializing in the design, production, and distribution of innovative, personalized, and sustainable solutions for joint replacement, sports medicine, and spine surgery. Founded in 1999 and headquartered in Castel San Pietro, it emphasizes minimally invasive procedures, personalized patient care, and extensive surgeon education through its M.O.R.E. Institute, supported by ongoing global R&D collaborations.

Average Trading Volume: 17,652

Technical Sentiment Signal: Buy

Current Market Cap: CHF3.08B

For detailed information about MOVE stock, go to TipRanks’ Stock Analysis page.